Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the European Union - Archives ouvertes des Sciences juridiques Access content directly
Reports Year : 2022

Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the European Union

Markus Frischhut
  • Function : Author
  • PersonId : 1165650
Tamara K. Hervey
  • Function : Author
  • PersonId : 1165651
Mary Guy
  • Function : Author
  • PersonId : 1165652
Inesa Fausch
  • Function : Author
  • PersonId : 1165727
Sabrina Röttger- Wirtz
  • Function : Author
  • PersonId : 1165728
Anne-Marie Duguet
  • Function : Author
  • PersonId : 918879
Isabelle Moine-Dupuis
Tomislav Sokol
  • Function : Author
  • PersonId : 1165729
Mathieu Guerriaud
Joaquin Cayon- de las Cuevas
  • Function : Author
  • PersonId : 1165730
Elena Petelos
  • Function : Author
Marko Ocokoljic
  • Function : Author
  • PersonId : 1165731
Charlotte Godziewski
  • Function : Author
  • PersonId : 1165732
Olivier Negre
  • Function : Author
Piotr Kolczynski
  • Function : Author
  • PersonId : 1165733
François Houÿez
  • Function : Author
  • PersonId : 1165734
Hrishikesh Kulkarni
  • Function : Author
  • PersonId : 1165735
Marcin Rodzinka- Verhelle
  • Function : Author
  • PersonId : 1165736
Tadeusz Hawrot
  • Function : Author
  • PersonId : 1165737

Abstract

On behalf of the Interest Group on Supranational Biolaw of the European Association of Health Law (EAHL IG Biolaw) and the I-BioLex research project (ANR-20-CE26-0007-01), Éloïse Gennet and Aurélie Mahalatchimy have been coordinating, since September 2021, the thematic network on the pharmaceutical strategy on the European Health Policy Platform (EUHPP) of the European Commission. The thematic network of the EAHL IG Biolaw, selected by the European Commission and by the users of the EUHPP platform, is entitled “Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the European Union”. This network enables to link the EAHL IG Biolaw, exclusively constituted by researchers and academics in the field of health law in Europe, on the one hand with the European Commission and in particular DG Health, and on the other hand with socio-economic actors interested in EU law applicable to medicinal products and medical devices (patient representatives, representatives of health professionals or non-governmental organizations in the field of health). After several months of fruitful exchanges, the final joint statement which was very favorably received by DG Health and endorsed by several organizations (including the President of Aix-Marseille University and the CNRS) has been presented at the EU Health Policy Platform Annual Meeting 2022 at the European Commission and published on the EUHPP in May 2022.

Domains

Law
Fichier principal
Vignette du fichier
EAHL IG BIOLAW - Inclusive Pharma Strategy - FINAL JOINT STATEMENT - 31.5.22.pdf (2.73 Mo) Télécharger le fichier
image (1).png (9.74 Ko) Télécharger le fichier
image (2).png (10.1 Ko) Télécharger le fichier
image.png (7.67 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

halshs-03780394 , version 1 (19-09-2022)

Identifiers

  • HAL Id : halshs-03780394 , version 1

Cite

Éloïse Gennet, Aurélie Mahalatchimy, Markus Frischhut, Pin Lean Lau, Tamara K. Hervey, et al.. Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the European Union. [Research Report] European Health Policy Platform of the European Commission. 2022. ⟨halshs-03780394⟩
235 View
87 Download

Share

Gmail Mastodon Facebook X LinkedIn More